
PMN
ProMIS Neurosciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.890
Open
0.829
VWAP
0.86
Vol
933.96K
Mkt Cap
27.61M
Low
0.8181
Amount
798.57K
EV/EBITDA(TTM)
--
Total Shares
18.96M
EV
19.21M
EV/OCF(TTM)
--
P/S(TTM)
--
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Show More
2 Analyst Rating

314.45% Upside
Wall Street analysts forecast PMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

314.45% Upside
Current: 0.844

Low
3.00
Averages
3.50
High
4.00

314.45% Upside
Current: 0.844

Low
3.00
Averages
3.50
High
4.00
H.C. Wainwright
Raghuram Selvaraju
initiated
$4
2025-07-14
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$4
2025-07-14
initiated
Reason
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences with a Buy rating and $4 price target. ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.
Maxim
NULL -> Buy
initiated
$3
2025-05-12
Reason
Maxim
Price Target
$3
2025-05-12
initiated
NULL -> Buy
Reason
Maxim initiated coverage of ProMIS Neurosciences with a Buy rating and $3 price target.
Guggenheim
Eddie Hickman
Strong Buy
Reiterates
$6
2025-04-01
Reason
Guggenheim
Eddie Hickman
Price Target
$6
2025-04-01
Reiterates
Strong Buy
Reason
Guggenheim
Eddie Hickman
Strong Buy
Reiterates
n/a
2025-02-26
Reason
Guggenheim
Eddie Hickman
Price Target
n/a
2025-02-26
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for ProMIS Neurosciences Inc (PMN.O) is -1.31, compared to its 5-year average forward P/E of -1.04. For a more detailed relative valuation and DCF analysis to assess ProMIS Neurosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.04
Current PE
-1.31
Overvalued PE
0.63
Undervalued PE
-2.71
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.08
Current EV/EBITDA
-0.94
Overvalued EV/EBITDA
-0.02
Undervalued EV/EBITDA
-2.14
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
2125.06
Current PS
0.00
Overvalued PS
6502.39
Undervalued PS
-2252.27
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+102.90%
-7.46M
Operating Profit
FY2025Q1
YoY :
+102.14%
-7.35M
Net Income after Tax
FY2025Q1
YoY :
+10.53%
-0.21
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
14.6K
USD
Months
0-12
4
268.2K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
14.6K
USD
Months
0-12
4
268.2K
USD
Months
PMN News & Events
Events Timeline
2025-07-28 (ET)
2025-07-28
07:08:32
ProMIS Neurosciences announces private placement financing

2025-07-22 (ET)
2025-07-22
07:18:11
ProMIS Neurosciences announces private placement financing

2025-07-22
07:16:35
ProMIS Neurosciences announces $0.8M registered direct offering

Sign Up For More Events
Sign Up For More Events
News
9.5
07-23BenzingaWhy Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
2.0
07-22TipRanks3 Penny Stocks to Watch Now, 7/22/25
4.5
07-21TipRanksMorning News Wrap-Up: Monday’s Biggest Stock Market Stories!
Sign Up For More News
People Also Watch

ZOOZ
Zooz Power Ltd
1.620
USD
-15.18%

DARE
Dare Bioscience Inc
2.385
USD
-3.83%

BCAB
Bioatla Inc
0.363
USD
+4.32%

SWIN
Solowin Holdings Ltd
3.930
USD
+2.61%

JOB
GEE Group Inc
0.200
USD
-3.85%

HUIZ
Huize Holding Ltd
2.260
USD
-7.68%

WKHS
Workhorse Group Inc
1.730
USD
+1.17%

COCH
Envoy Medical Inc
1.557
USD
+2.43%

CMBM
Cambium Networks Corp
0.919
USD
+10.06%

NXPL
NextPlat Corp
0.710
USD
-0.14%
FAQ

What is ProMIS Neurosciences Inc (PMN) stock price today?
The current price of PMN is 0.844499 USD — it has increased 0.48 % in the last trading day.

What is ProMIS Neurosciences Inc (PMN)'s business?

What is the price predicton of PMN Stock?

What is ProMIS Neurosciences Inc (PMN)'s revenue for the last quarter?

What is ProMIS Neurosciences Inc (PMN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ProMIS Neurosciences Inc (PMN)'s fundamentals?

How many employees does ProMIS Neurosciences Inc (PMN). have?
